Safety and efficacy of brentuximab vedotin (BV) as monotherapy or in combination with bendamustine (BV-B) in relapsed refractory classic hodgkin lymphoma (CHL).

Trial Profile

Safety and efficacy of brentuximab vedotin (BV) as monotherapy or in combination with bendamustine (BV-B) in relapsed refractory classic hodgkin lymphoma (CHL).

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Dec 2017

At a glance

  • Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Dec 2017 New trial record
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top